全文获取类型
收费全文 | 102篇 |
免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 1篇 |
妇产科学 | 1篇 |
基础医学 | 8篇 |
临床医学 | 14篇 |
内科学 | 34篇 |
神经病学 | 9篇 |
特种医学 | 3篇 |
外科学 | 11篇 |
预防医学 | 1篇 |
眼科学 | 1篇 |
药学 | 4篇 |
肿瘤学 | 15篇 |
出版年
2021年 | 2篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2018年 | 3篇 |
2017年 | 1篇 |
2016年 | 1篇 |
2014年 | 4篇 |
2013年 | 7篇 |
2012年 | 6篇 |
2011年 | 6篇 |
2010年 | 2篇 |
2009年 | 4篇 |
2008年 | 9篇 |
2007年 | 8篇 |
2006年 | 9篇 |
2005年 | 10篇 |
2004年 | 10篇 |
2003年 | 2篇 |
2002年 | 3篇 |
2001年 | 3篇 |
1999年 | 2篇 |
1995年 | 1篇 |
1990年 | 1篇 |
1988年 | 1篇 |
1984年 | 1篇 |
1873年 | 3篇 |
1871年 | 1篇 |
排序方式: 共有103条查询结果,搜索用时 125 毫秒
81.
82.
Prousalidis J Kosmidis C Kapoutzis K Fachantidis E Harlaftis N Aletras H 《American journal of surgery》2009,198(2):193-198
Background
Intrabiliary rupture is a common and serious complication of hepatic hydatidosis, and its treatment remains controversial.Methods
Sixty-seven patients who underwent surgery for rupture of a hydatid cyst in the biliary tree were studied retrospectively. The following data were analyzed: age, sex, clinical presentation, and so on.Results
In 55 patients, intrabiliary rupture was diagnosed preoperatively and in 12 patients intraoperatively. In 51 patients, partial pericystectomy and closed-tube drainage followed. Pericystorraphy was performed in 9 patients. Omentoplasty was performed in 5 cases. After the meticulous cleansing of the common bile duct, T-tube drainage (60 patients), choledochoduodenostomy (4 patients), or sphincteroplasty (1 patient) was added. In 4 patients, there was a persisting external biliary fistula. The mean length of hospital stay was 18 days. Follow up (1-35 years) elicited 4 recurrences and 1 postoperative death.Conclusions
Our results in intrabiliary rupture of echinococcal cysts are considered to be satisfactory. Surgical treatment can be improved with the modern methods of investigation, wider use of newer chemotherapeutics, and appropriate modification of surgical procedures. 相似文献83.
84.
85.
A randomized controlled trial of pentoxifylline for the prevention of post-ERCP pancreatitis 总被引:1,自引:0,他引:1
Kapetanos D Kokozidis G Christodoulou D Mistakidis K Sigounas D Dimakopoulos K Kitis G Tsianos EV 《Gastrointestinal endoscopy》2007,66(3):513-518
BACKGROUND: Pentoxifylline can ameliorate pancreatitis in animal models because of its anti-tumor necrosis factor properties. OBJECTIVE: Our purpose was to study the safety and efficacy of pentoxifylline in the prevention of post-ERCP pancreatitis. DESIGN: Patients due to undergo ERCP for various indications were randomized to receive pentoxifylline 400 mg orally 3 times, beginning the day before ERCP (2 and 10 pm) until the night after the procedure (6 am and 2 and 10 pm) or to receive no preventive medication. Serum amylase values were determined before and 6 and 24 hours after ERCP. Diagnosis and grading of the severity of complications was performed according to consensus criteria. PATIENTS: One hundred fifty-eight patients received pentoxifylline (group A) and 162 had no medication (group B). The groups were similar in distributions of sex, biliary sphincterotomy, pancreatography, pancreatic duct cannulations, stone extraction, stent placement, and presence of periampullary diverticulum. Group A patients were younger (mean age 63 vs 68 years, P<.05) and biliary colic was a more frequent indication (30 vs 12, P<.05). RESULTS: Nine (5.6%) patients in group A and 5 (3%) in group B had pancreatitis (2 and 1 severe, respectively; P=.28). Serum amylase values were similar in baseline and 6- and 24-hour samples. Two (1.2%) patients in group A and 7 (4.3%) in group B had hemorrhage. LIMITATIONS: This was not a double-blind trial. CONCLUSIONS: In this study pentoxifylline did not protect against post-ERCP pancreatitis or hyperamylasemia. 相似文献
86.
87.
Zakynthinos E Theodorakopoulou M Daniil Z Konstantinidis K Zakynthinos S 《Heart & lung : the journal of critical care》2004,33(1):55-60
PURPOSE: The purpose of this study was to report the development, management, and follow up of tamponading uremic pericardial effusion in critically ill patients with acute renal failure. SETTING: The setting for this study was an adult, 24-bed tertiary multidisciplinary intensive care unit (ICU) of a university hospital. PATIENTS: The subjects were 5 critically ill patients with multiple organ failure including acute renal failure (ARF) that was slow to resolve. RESULTS: Renal involvement was attributed to renal hypoperfusion, sepsis and myoglobinuria. Continuous veno-venous hemofiltration (CVVH) was instituted early during hospitalization in 4 cases and lasted for 35 to 48 days; renal replacement therapy was not used in 1 case. Tamponade developed late in the course of ARF, after CVVH was discontinued in the 4 cases and was effectively managed with percutaneous pericardiocentesis under echocardiography and continuous catheter drainage of the pericardial sac for 48 to 72 hours. Hemorrhagic fluid (Hb 2.2-5.9 g/dL) with lymphocyte predominance was detected. Transient constrictive-like pericarditis findings were present in all patients after the procedure. All patients were discharged from the hospital in a good condition with normal serum and creatinine levels; 1-year follow up showed a normal echocardiogram. CONCLUSION: Awareness for the possibility of hemorrhagic pericarditis and cardiac tamponade is needed in ICU patients with ARF slow to resolve. Transient constrictive-like pericarditis may present after pericardiocentesis. 相似文献
88.
Pectasides D Papaxoinis G Kalogeras K Eleftheraki A Xanthakis I Makatsoris T Samantas E Varthalitis I Papakostas P Nikitas N Papandreou CN Pentheroudakis G Timotheadou E Koutras A Sgouros J Bafaloukos D Klouvas G Economopoulos T Syrigos KN Fountzilas G 《BMC cancer》2012,12(1):271
ABSTRACT: BACKGROUND: The aim was to compare two standard chemotherapy regimens combined with bevacizumab as first-line treatment in patients with metastatic colorectal cancer. METHODS: Patients previously untreated for metastatic disease were randomized in: group A (irinotecan, capecitabine, bevacizumab, every 3 weeks; XELIRI-bevacizumab) and group B (irinotecan, leucovorin, fluorouracil, bevacizumab, every 2 weeks; FOLFIRI-bevacizumab). Primary endpoint was progression-free survival (PFS). Plasma concentrations of nitric oxide, osteopontin, TGF-1 and VEGF-A were measured at baseline and during treatment. RESULTS: Among 285 eligible patients, 143 were randomized to group A and 142 to group B. Fifty-five patients (38.5%) in group A and 57 (40.1%) in group B responded (p=0.81). After a median follow-up of 42 months, median PFS was 10.2 and 10.8 months (p=0.74), while median OS was 20.0 and 25.3 months (p=0.099), for groups A and B, respectively. Most frequent grade 3-4 toxicities (group A vs group B) were neutropenia (13% vs 22%, p=0.053) and diarrhea (19% vs 11%, p=0.082). Baseline plasma osteopontin concentrations demonstrated prognostic significance for both PFS and OS. CONCLUSIONS: This trial did not show significant differences in efficacy between the groups. However, the toxicity profile was different. Baseline plasma osteopontin concentrations demonstrated independent prognostic significance. (Registration number: ACTRN12610000270011). 相似文献
89.
Dr. Epaminondas Kotsonopulos 《Virchows Archiv : an international journal of pathology》1873,57(1):143-143
Ohne Zusammenfassung 相似文献
90.
Stylianos Ravanidis MSc PhD Anastasia Bougea MD PhD Nikolaos Papagiannakis MD PhD Matina Maniati MSc PhD Christos Koros MD PhD Athina-Maria Simitsi MD MSc Maria Bozi MD PhD Ioanna Pachi MD Maria Stamelou MD PhD George P. Paraskevas MD PhD Elisabeth Kapaki MD PhD Marina Moraitou PhD Helen Michelakakis PhD Leonidas Stefanis MD PhD Epaminondas Doxakis MSc PhD MBA 《Movement disorders》2020,35(3):457-467